{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:44:29Z","timestamp":1792525469657,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinthera.2026.09.014","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:28:51Z","timestamp":1792438131000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time-matched Secondary Fracture Prevention in Older Adults: A Narrative Review of Imminent Risk, Time-to-Benefit, and Treatment Sequencing"],"prefix":"10.1016","author":[{"given":"Zudong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbiao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0001","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jbmr.4821","article-title":"Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality","volume":"38","author":"Sing","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.clinthera.2026.09.014_bib0002","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0003","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00198-024-07052-1","article-title":"Effectiveness of fracture liaison service in reducing the risk of secondary fragility fractures in adults aged 50 and older: a systematic review and meta-analysis","volume":"35","author":"Danazumi","year":"2024","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40744-024-00743-5","article-title":"Real-world osteoporosis treatment gap and costs in Spain: data from women with a first fragility fracture or diagnosis of postmenopausal osteoporosis","volume":"12","author":"Sicras-Mainar","year":"2025","journal-title":"Rheumatol Ther"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0005","first-page":"1061","article-title":"Zoledronic acid for hip fracture during initial hospitalization","volume":"39","author":"Fan","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.21106","article-title":"Prevalence of osteoporosis and fracture in China: the China Osteoporosis Prevalence Study","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.clinthera.2026.09.014_bib0007","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11657-025-01588-3","article-title":"The 2024 UK clinical guideline for the prevention and treatment of osteoporosis","volume":"20","author":"Gregson","year":"2025","journal-title":"Arch Osteoporos"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0009","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Clinical Guidelines Committee of the American College of Physicians, et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.clinthera.2026.09.014_bib0010","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA: a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00198-021-06166-0","article-title":"Time dependency in early major osteoporotic and hip re-fracture in women and men aged 50 years and older: a population-based observational study","volume":"33","author":"Leslie","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0014","article-title":"Exploring mortality risk factors and specific causes of death within 30 days after hip fracture hospitalization","volume":"14","author":"Wu","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.clinthera.2026.09.014_bib0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.clinthera.2026.09.014_bib0016","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clinthera.2026.09.014_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0018","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1359\/jbmr.090207","article-title":"Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001","volume":"24","author":"Ryg","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0019","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jamainternmed.2021.6745","article-title":"Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials","volume":"182","author":"Deardorff","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians","volume":"176","author":"Ayers","year":"2023","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0022","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/jbmr.1605","article-title":"Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.1016\/j.clinthera.2026.09.014_bib0023","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0024","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clinthera.2026.09.014_bib0025","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10117","key":"10.1016\/j.clinthera.2026.09.014_bib0026","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.clinthera.2026.09.014_bib0027","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clinthera.2026.09.014_bib0028","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"9999","key":"10.1016\/j.clinthera.2026.09.014_bib0029","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clinthera.2026.09.014_bib0030","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","article-title":"Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0031","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0032","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0033","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0036","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0037","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.clinthera.2026.09.014_bib0038","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0039","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"18","key":"10.1016\/j.clinthera.2026.09.014_bib0069","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.014_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116298","article-title":"Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery","volume":"155","author":"Kashii","year":"2022","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0058","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M24-0013","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease: a target trial emulation","volume":"178","author":"Bird","year":"2025","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0041","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2106\/JBJS.24.00766","article-title":"A Hip New Standard: improving osteoporosis care with inpatient administration of IV zoledronate","volume":"107","author":"Turner","year":"2025","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0042","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group","volume":"25","author":"Siris","year":"2014","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.clinthera.2026.09.014_bib0043","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement","volume":"333","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2026.09.014_bib0044","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221112904","article-title":"Timing of osteoporosis therapies following fracture: the current status","volume":"13","author":"Palui","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00198-014-2903-2","article-title":"Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Li","year":"2015","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0046","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00198-010-1473-1","article-title":"Association between timing of zoledronic acid infusion and hip fracture healing","volume":"22","author":"Colon-Emeric","year":"2011","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.clinthera.2026.09.014_bib0047","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.2301","article-title":"The osteoporosis treatment gap","volume":"29","author":"Kanis","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0048","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","article-title":"Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures","volume":"28","author":"Harvey","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.clinthera.2026.09.014_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0844","article-title":"Osteoporosis treatment after hip fracture: bad news and getting worse","volume":"1","author":"Bauer","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0050","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00198-011-1630-1","article-title":"A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving","volume":"23","author":"Leslie","year":"2012","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.clinthera.2026.09.014_bib0051","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-017-4175-0","article-title":"Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis","volume":"28","author":"Saito","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0052","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00198-016-3811-4","article-title":"Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study","volume":"28","author":"Shah","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0053","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12877-025-06871-z","article-title":"Subsequent fracture risk after hip fracture surgery in China: a three-year retrospective cohort study","volume":"26","author":"Yuan","year":"2025","journal-title":"BMC Geriatr"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0054","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12877-023-03778-5","article-title":"Exploring the osteoporosis treatment gap after fragility hip fracture at a tertiary university medical center in Thailand","volume":"23","author":"Mahaisavariya","year":"2023","journal-title":"BMC Geriatr"},{"issue":"11","key":"10.1016\/j.clinthera.2026.09.014_bib0055","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00198-025-07697-6","article-title":"Adherence to secondary fracture prevention is associated with reduced risk of subsequent fractures","volume":"36","author":"Bjornerem","year":"2025","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.clinthera.2026.09.014_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.clinthera.2026.09.014_bib0057","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.clinthera.2026.09.014_bib0059","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2026.09.014_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0061","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1210\/clinem\/dgz321","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study","volume":"105","author":"Lyu","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.clinthera.2026.09.014_bib0062","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.clinthera.2026.09.014_bib0063","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11657-024-01453-9","article-title":"Inpatient zoledronic acid in older hip fracture patients is well tolerated and safe","volume":"19","author":"Malgo","year":"2024","journal-title":"Arch Osteoporos"},{"issue":"11","key":"10.1016\/j.clinthera.2026.09.014_bib0066","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1111\/jgs.70060","article-title":"Preliminary data from a geriatrician-led program for orthopedic co-managed hip fracture patients using zoledronic acid","volume":"73","author":"Chahal","year":"2025","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.clinthera.2026.09.014_bib0067","article-title":"Achieving 100% uptake of intravenous zoledronic acid after hip fracture through rapid vitamin D loading: a three-cycle quality improvement study in a district general hospital","volume":"17","author":"Wilson","year":"2025","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.clinthera.2026.09.014_bib0068","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/agm2.12229","article-title":"Improving osteoporosis treatment rates in inpatients admitted with hip fracture: a healthcare improvement initiative in a tertiary referral hospital","volume":"5","author":"Lin","year":"2022","journal-title":"Aging Med (Milton)"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00198-024-07325-9","article-title":"The impact of a fracture liaison service with in-hospital anti-osteoporosis treatment on subsequent hip fracture and mortality rates-a single-center retrospective study","volume":"36","author":"Yoel","year":"2025","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0071","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/os.12517","article-title":"Anti-osteoporosis medications associated with decreased mortality after hip fracture","volume":"11","author":"Wang","year":"2019","journal-title":"Orthop Surg"},{"issue":"3","key":"10.1016\/j.clinthera.2026.09.014_bib0072","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","article-title":"Oral bisphosphonates are associated with reduced mortality after hip fracture","volume":"22","author":"Beaupre","year":"2011","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.clinthera.2026.09.014_bib0073","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad172","article-title":"Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture","volume":"52","author":"Johansen","year":"2023","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0074","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","article-title":"Recommendations for the optimal use of bone forming agents in osteoporosis","volume":"36","author":"Veronese","year":"2024","journal-title":"Aging Clin Exp Res"},{"issue":"12","key":"10.1016\/j.clinthera.2026.09.014_bib0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s00198-003-1507-z","article-title":"The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture","volume":"14","author":"McLellan","year":"2003","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0076","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00198-012-2090-y","article-title":"Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis","volume":"24","author":"Ganda","year":"2013","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0077","first-page":"1071","article-title":"Following hip fracture, hospital organizational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study","volume":"39","author":"Patel","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0078","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00198-013-2348-z","article-title":"Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle","volume":"24","author":"Akesson","year":"2013","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0079","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00198-020-05377-1","volume":"31","author":"Javaid","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2026.09.014_bib0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2018.03.018","article-title":"Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis","volume":"111","author":"Wu","year":"2018","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0081","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-018-0463-3","article-title":"Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region","volume":"13","author":"Chan","year":"2018","journal-title":"Arch Osteoporos"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0082","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00198-019-05197-y","article-title":"Secondary prevention of fragility fractures in Asia Pacific: an educational initiative","volume":"31","author":"Ebeling","year":"2020","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0083","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11657-026-01691-z","article-title":"Digitally enhanced fracture liaison service in Austria: a feasibility analysis","volume":"21","author":"Pfender","year":"2026","journal-title":"Arch Osteoporos"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0084","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11657-025-01524-5","article-title":"Breaking the silence: AI's contribution to detecting vertebral fractures in opportunistic CT scans in the elderly: a validation study","volume":"20","author":"Spangeus","year":"2025","journal-title":"Arch Osteoporos"},{"issue":"1\u20132","key":"10.1016\/j.clinthera.2026.09.014_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10354-024-01066-4","article-title":"Sentinel fracture: the necessity of improved post-fracture care","volume":"175","author":"Kerschan-Schindl","year":"2025","journal-title":"Wien Med Wochenschr"},{"issue":"2","key":"10.1016\/j.clinthera.2026.09.014_bib0086","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00198-024-07269-0","article-title":"Impact of the guidance on fracture liaison services and the introduction of a new fee for secondary fracture prevention in Japan: implementation of secondary fracture prevention during hospitalization for fragility fractures","volume":"36","author":"Gondo","year":"2025","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.clinthera.2026.09.014_bib0087","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00198-025-07721-9","article-title":"Impact of a national reimbursement policy on anti-osteoporosis medication prescription at discharge after hip-fracture surgery in Japan: an interrupted time-series analysis","volume":"36","author":"Takegami","year":"2025","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0088","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","article-title":"An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study","volume":"4","author":"Cheung","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"issue":"8","key":"10.1016\/j.clinthera.2026.09.014_bib0089","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003180","article-title":"Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study","volume":"17","author":"Zhang","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11657-024-01375-6","article-title":"Survey of awareness and attitudes to the management of fragility fractures among the membership of the Asia Pacific Orthopaedic Association","volume":"19","author":"Lee","year":"2024","journal-title":"Arch Osteoporos"},{"issue":"7","key":"10.1016\/j.clinthera.2026.09.014_bib0091","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00198-020-05742-0","article-title":"Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region","volume":"32","author":"Chandran","year":"2021","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.clinthera.2026.09.014_bib0092","first-page":"573","article-title":"Guideline for the diagnosis and management of primary osteoporosis (2022 edition)","volume":"15","year":"2022","journal-title":"Chin J Osteoporos Bone Miner Res"},{"key":"10.1016\/j.clinthera.2026.09.014_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116216","article-title":"Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: a nationwide population study","volume":"154","author":"Tai","year":"2022","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.clinthera.2026.09.014_bib0094","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"39","key":"10.1016\/j.clinthera.2026.09.014_bib0095","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.221647","article-title":"Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update","volume":"195","author":"Morin","year":"2023","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.clinthera.2026.09.014_bib0096","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause."},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0097","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.clinthera.2026.09.014_bib0098","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.09.014_bib0099","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-based guideline for the management of osteoporosis in men","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.09.014_bib0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamda.2015.01.073","article-title":"Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis","volume":"16","author":"Zarowitz","year":"2015","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"10.1016\/j.clinthera.2026.09.014_bib0101","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.clinthera.2026.09.014_bib0102","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/jgs.15725","article-title":"Effect of bisphosphonates on fracture outcomes among frail older adults","volume":"67","author":"Zullo","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.clinthera.2026.09.014_bib0103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2026.09.014_bib0104","unstructured":"Zoledronic acid given early after hip fracture (ZOLearly). ClinicalTrials.gov. Identifier: NCT05025293. Updated September 7, 2021. Accessed July 25, 2026."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600353X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600353X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:23:55Z","timestamp":1792524235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182600353X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":104,"alternative-id":["S014929182600353X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-matched Secondary Fracture Prevention in Older Adults: A Narrative Review of Imminent Risk, Time-to-Benefit, and Treatment Sequencing","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}